Cite
HARVARD Citation
Masanas, M. et al. (2021). The oral KIF11 inhibitor 4SC‐205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models. Clinical and translational medicine. 11 (10), p. n/a. [Online].